WithdrawnPhase 3NCT01940315

Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B

Studying Botulism

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
DynPort Vaccine Company LLC, A GDIT Company
Principal Investigator
George A Saviolakis, M.D., Ph.D.
DynPort Vaccine Company LLC, A GDIT Company
Intervention
rBV A/B(biological)
Eligibility
18-55 years · All sexes
Timeline
2017 – 2019

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01940315 on ClinicalTrials.gov

Other trials for Botulism

Additional recruiting or active studies for the same condition.

See all trials for Botulism →

← Back to all trials